Adherence to a Recommended Exercise Regimen in Colorectal Cancer Patients

Status Completed

Clinical Trial Summary

Given the apparent effect of 18 metabolic equivalent task-hours of activity/week in improving disease free survival in patients with treated stage 3 colon cancer and the survival benefit of exercise demonstrated in patients with stage II and III colorectal cancer, the primary objective is to evaluate compliance at 6 months with post-treatment recommendations for a minimum of 18 metabolic units of physical activity each week in patients who have completed therapy for stage 2 and stage 3 colorectal cancer.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00977613
Study type	Interventional
Source	Beth Israel Medical Center
Contact
Status	Completed
Phase	N/A
Start date	April 2007
Completion date	May 2010

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06040541` - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors	Phase 1
Completed	`NCT01450319` - A Phase 2 Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype	Phase 2
Recruiting	`NCT05462717` - Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors	Phase 1
Recruiting	`NCT04083599` - GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors	Phase 1/Phase 2
Completed	`NCT02903914` - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Terminated	`NCT03253185` - A Study of SC-007 in Subjects With Advanced Cancer	Phase 1
Completed	`NCT00851045` - Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT06026410` - KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors	Phase 1
Recruiting	`NCT04622423` - Advanced Therapies for Liver Metastases
Active, not recruiting	`NCT02955940` - An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib	Phase 2
Completed	`NCT02327078` - A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)	Phase 1/Phase 2
Completed	`NCT03314935` - A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05379985` - Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS	Phase 1
Recruiting	`NCT05648955` - Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment	Early Phase 1
Completed	`NCT00165854` - Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT05706129` - A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT02646748` - Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT02005913` - A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence	N/A
Recruiting	`NCT04256707` - Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment	Phase 1/Phase 2
Recruiting	`NCT04792684` - Collection of Samples USOPTIVAL Study